ONTX Share Price | Traws Pharma, Inc. Stock Analysis & Recommendation

Q: How big is Traws Pharma, Inc.?

Market Cap: As of Jun 18, Traws Pharma, Inc. has a market capitalization of 9.24 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Traws Pharma, Inc. reported net sales of 0.24 million and a net profit of -34.60 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -31.63 million, while total assets were reported at 24.96 million.

Q: What does Traws Pharma, Inc. do?

Overview: Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 15 Million (Quarterly Results - Mar 2025) Market-cap: USD 9.24 Million (Micro Cap) Key Metrics: P/E: 0.00 Debt Equity: -2.66 Return on Equity: 939.05% Price to Book: 1.54 Contact Details: Address: 375 Pheasant Run, NEWTOWN PA: 18940-3423 Tel: 1 267 7593680 Fax: 1 267 7593681 Website: https://www.onconova.com/

Q: Is Traws Pharma, Inc. technically bullish or bearish?

As of 2 June 2025, the technical trend for Traws Pharma, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD and Dow Theory show mildly bullish signals. The Bollinger Bands present a mixed view with weekly bullishness and monthly mild bearishness. The stock has significantly underperformed the S&P 500 over multiple periods, with a year-to-date return of -76.80% compared to the S&P's 12.22%.

Q: Is Traws Pharma, Inc. overvalued or undervalued?

As of 21 November 2025, Traws Pharma, Inc. has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued, particularly when considering its strong financial metrics, including a P/E ratio of 0, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. When compared to peers, Traws Pharma's valuation ratios stand out; for instance, Catalyst Biosciences, Inc. has a P/E ratio of 110.04, indicating it is expensive relative to Traws. Additionally, Elutia, Inc. shows a risky profile with an EV to EBITDA of -5.54, further highlighting Traws Pharma's relative strength. Despite a challenging year with a YTD return of -72.64% compared to the S&P 500's 12.26%, Traws Pharma's three-year return of 191.72% suggests significant potential for recovery and growth.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

27.78 k

Shareholding (Sep 2025)

FII

0.05%

Held by 7 FIIs

DII

89.88%

Held by 2 DIIs

Promoter

8.57%

How big is Traws Pharma, Inc.?

22-Jun-2025

As of Jun 18, Traws Pharma, Inc. has a market capitalization of 9.24 million and reported net sales of 0.24 million with a net profit of -34.60 million over the last four quarters. The company's shareholder's funds are -31.63 million, with total assets of 24.96 million.

View full answer

What does Traws Pharma, Inc. do?

22-Jun-2025

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs for cancer treatment. As of March 2025, it has a market cap of $9.24 million, with net sales of $0 million and a net profit of $15 million.

View full answer

Who are in the management team of Traws Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Traws Pharma, Inc. includes Mr. James Marino (Chairman), Dr. Steven Fruchtman (President and CEO), and Directors Dr. Henry Bienen, Dr. Jerome Groopman, Dr. Viren Mehta, Ms. Terri Shoemaker, and Mr. Jack Stover. They oversee the company's operations and strategic direction.

View full answer

Is Traws Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of June 2, 2025, Traws Pharma, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly indicators present mixed signals, and the stock has underperformed the S&P 500 with a year-to-date return of -76.80%.

View full answer

Is Traws Pharma, Inc. overvalued or undervalued?

25-Nov-2025

As of November 21, 2025, Traws Pharma, Inc. is considered very attractive due to its strong financial metrics, including a P/E ratio of 0, an EV to EBIT of 0.14, and a remarkable ROE of 939.05%, despite a challenging year with a YTD return of -72.64%, indicating significant potential for recovery compared to its peers.

View full answer

Compare Traws Pharma, Inc. with Similar Stocks

Applied DNA Sciences, Inc.Microbot Medical, Inc.BiomX, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared positive results for the last 2 consecutive quarters

NET SALES(HY) At USD 2.73 MM has Grown at 2,297.37%
ROCE(HY) Highest at 7,432.32%
PRE-TAX PROFIT(Q) At USD -3.96 MM has Grown at 53.29%

With ROE of 1467.41%, it has a very attractive valuation with a 3.71 Price to Book Value

High Institutional Holdings at 26.27%

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 17 Million (Micro Cap)

P/E

0.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.41

Return on Equity

1,467.41%

Price to Book

3.71

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

61.29%

6 Months

7.53%

1 Year

-29.58%

2 Years

-90.78%

3 Years

173.97%

4 Years

-95.74%

5 Years

-99.43%

Traws Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.56%

EBIT Growth (5y)

-18.65%

EBIT to Interest (avg)

-21.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.66

Sales to Capital Employed (avg)

0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

26.27%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.71

EV to EBIT

-0.26

EV to EBITDA

-0.26

EV to Capital Employed

-5.57

EV to Sales

3.67

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

1467.41%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 2 Schemes (1.5%)

Foreign Institutions

Held by 7 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -100.00% vs 0.00% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 64.71% vs -80.85% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-8.50",
          "chgp": "52.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.00",
          "val2": "-8.50",
          "chgp": "64.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-149,754.40%",
          "chgp": "14,975.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -189.42% vs 0.53% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-49.30",
          "val2": "-20.30",
          "chgp": "-142.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-117.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.70",
          "val2": "-18.90",
          "chgp": "-189.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-218,354.00%",
          "val2": "-89,814.20%",
          "chgp": "-12,853.98%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

0.10

-100.00%

Operating Profit (PBDIT) excl Other Income

-4.00

-8.50

52.94%

Interest

0.00

Exceptional Items

-0.00

0.00

Consolidate Net Profit

-3.00

-8.50

64.71%

Operating Profit Margin (Excl OI)

0.00%

-149,754.40%

14,975.44%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is -100.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 64.71% vs -80.85% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.20

Operating Profit (PBDIT) excl Other Income

-49.30

-20.30

-142.86%

Interest

0.00

Exceptional Items

-117.50

0.00

Consolidate Net Profit

-54.70

-18.90

-189.42%

Operating Profit Margin (Excl OI)

-218,354.00%

-89,814.20%

-12,853.98%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -189.42% vs 0.53% in Dec 2023

All Annual Results

Company CV

About Traws Pharma, Inc.

Traws Pharma, Inc.

Pharmaceuticals & Biotechnology

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Company Coordinates

Company Details

375 Pheasant Run , NEWTOWN PA : 18940-3423

Tel: 1 267 7593680

https://www.onconova.com/

Registrar Details